Suscribirse

Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies - 10/06/22

Doi : 10.1016/j.clinre.2022.101912 
Dominique Béchade a, b, , Carine Bellera c, d, Lisa Gauquelin c, Isabelle Soubeyran e, Pippa McKelvie-Sebileau f, Marc Debled a, François Chomy a, Guilhem Roubaud a, Marianne Fonck a, Simon Pernot a, b, Alexandre Roch g, Anne-Laure Cazeau g
a Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France 
b Univ. Bordeaux, 146 rue Léo Saignat, 33000 Bordeaux, France 
c Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux, France 
d Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000 Bordeaux, France 
e Department of Pathology, Institut Bergonié, 33076 Bordeaux, France 
f University of Auckland, Auckland, New Zealand 
g Department of Nuclear Medicine, Institut Bergonié, 33076 Bordeaux, France 

Corresponding author: Dominique Béchade, Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux, France.Department of Medical OncologyInstitut Bergonié229 cours de l'ArgonneBordeaux33076France

HIGHLIGHTS

From: Contrast Media Mol Imaging, volume 28, 2018, pages 1-9.
PET-CT has a high sensitivity in assessing cancer extension.
The specificity is much lower, especially for mediastinal lymph nodes in an oncologic context.
Clinical dilemnas may arise during the initial management of a cancer, evaluation of treatment, or monitoring.
In some cases, accurate pathological diagnosis is essential for the initial staging of primary thoracic or extra-thoracic malignancies, or for detecting recurrence in patients with treated malignancies.
From: Am J gastroenterol, volume 95, 2000, pages 2278-2284.
EUS-FNA is a minimally invasive, safe and effective technique.
EUS-FNA shows that hypermetabolic lymph nodes may be due to granulomatous or infectious lesions in an oncological context.
From: Dig Dis Sci, Volume 66, August 2021, Pages 2763-2775.
EUS-FNA is a sensitive, highly specific, and safe method for distinguishing between benign and malignant mediastinal lymphadenopathies.
Our results indicate high sensitivity and excellent specificity.
In our prospective study, we conclude that the diagnostic accuracy of EUS-FNA, without ROSE, is sufficiently robust to avoid the need for a surgical diagnosis.
EUS-FNA made it possible to diagnose 46.8% of granulomatous adenopathies at different stages of the management of thoracic or extra-thoracic cancers.
The combination of PET-CT and EUS-FNA may alter the therapeutic strategy that would have been considered after PET-CT alone.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

The high sensitivity of PET-CT can identify hypermetabolic mediastinal adenopathies during cancer management, but specificity is low and a biopsy is sometimes required to eliminate benign adenopathies.

Methods

This prospective diagnostic accuracy study included patients with hypermetabolic mediastinal lymphadenopathies revealed on PET-CT during either the initial management of a cancer, treatment evaluation, or monitoring. All patients underwent EUS-FNA. Diagnoses of malignancy based on cytological analysis following EUS-FNA were compared with clinical and radiological follow-up information. The treatment strategy decided before the results of the EUS-FNA pathology reports (Multidisciplinary Team Meeting [MTM-1]) was recorded and compared to the treatment strategy decided once pathological data from EUS-FNA were available (MTM-2).

Main findings

Between 2013 and 2018, 75 patients were included with 47 eligible and evaluable patients. Sensitivity, specificity, and positive and negative predictive values of EUS-FNA were 93%, 100%, 100% and 90%, respectively. The concordance value between the therapeutic strategies determined for MTM-1 and MTM-2 was 44.7%. There were no significant differences in the intensity of fixation on PET-CT between malignant and benign lesions.

Conclusion

The diagnostic accuracy of the minimally invasive EUS-FNA procedure is sufficiently robust to avoid the need for diagnostic surgery. The combination of PET-CT and EUS-FNA may alter the therapeutic strategy that would be considered after PET-CT alone.

REGISTRATION

NCT01892501

El texto completo de este artículo está disponible en PDF.

Keywords : endoscopic ultrasound-guided fine-needle aspiration, mediastinal lymphadenopathy, Positron Emission Tomography - Computed Tomography, clinical impact on cancer management


Esquema


© 2022  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 46 - N° 5

Artículo 101912- mai 2022 Regresar al número
Artículo precedente Artículo precedente
  • Endoscopic ultrasound guided fine needle biopsy in patients with suspected gastric linitis plastica
  • Antoine Assaf, Benoit Terris, Lola-Jade Palmieri, Alexandre Rouquette, Frédéric Beuvon, Anna Pellat, Einas Abou Ali, Claire Ginestet, Arthur Belle, Dr Marion Dhooge, Dr Catherine Brezault, Rachel Hallit, Anthony Dohan, Stanislas Chaussade, Romain Coriat, Maximilien Barret
| Artículo siguiente Artículo siguiente
  • Endoscopic anti-reflux mucosectomy (ARMS): A new therapeutic option in the treatment of gerd in case of oesophageal atresia?
  • Ivann Bouteiller, Marine Guingand, Pascal- Alexandre Thomas, Jean-Michel Gonzalez, Veronique Vitton

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.